Evidence map›Paper›PMID 30655837›Full record

ArticleOncology letters2019

miR-205 targets runt-related transcription factor 2 to inhibit human pancreatic cancer progression.

Lu Zhuang, Jia Guo, Yao Yao, Zhaoshen Li

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. microRNA-205 in prostate cancer: Overview to clinical translation.Biochimica et biophysica acta. Reviews on cancer · 2022
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Lu ZhuangDepartment of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China.
Jia GuoDepartment of Cancer Biology, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
Yao YaoDepartment of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China.
Zhaoshen LiDepartment of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China.
Second Military Medical University · CNChanghai Hospital · CNMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have demonstrated that microRNAs (miRs) serve important roles in the progression of human cancer types, including pancreatic cancer (PC), a highly lethal malignancy. In the past few decades, several miRs have been identified to be associated with the overall survival of patients with PC and have been demonstrated to be potential therapeutic targets. However, to the best of our knowledge, the association between miR-205 expression and the progression of PC has rarely been investigated. In the current study, low miR-205 expression was revealed in PC tumor tissues and indicated poor prognosis in patients with PC. In addition, miR-205 overexpression reduced and miR-205 depletion enhanced PC cell proliferation and migration

Indexed as

cancer progressionmicroRNA-205pancreatic cancerrunt-related transcription factor 2

Identifiers

PMID30655837
PMCPMC6313060
OpenAlexW2901956131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.